272 related articles for article (PubMed ID: 27650757)
1. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging.
Blake L; Duarte RV; Cummins C
BMJ Open; 2016 Sep; 6(9):e010507. PubMed ID: 27650757
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Bresnahan R; Duarte R; Mahon J; Beale S; Chaplin M; Bhattacharyya D; Houten R; Edwards K; Nevitt S; Maden M; Boland A
Health Technol Assess; 2023 Jul; 27(10):1-115. PubMed ID: 37839810
[TBL] [Abstract][Full Text] [Related]
3. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.
Eddowes PJ; McDonald N; Davies N; Semple SIK; Kendall TJ; Hodson J; Newsome PN; Flintham RB; Wesolowski R; Blake L; Duarte RV; Kelly CJ; Herlihy AH; Kelly MD; Olliff SP; Hübscher SG; Fallowfield JA; Hirschfield GM
Aliment Pharmacol Ther; 2018 Mar; 47(5):631-644. PubMed ID: 29271504
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease.
Schaapman JJ; Tushuizen ME; Coenraad MJ; Lamb HJ
J Magn Reson Imaging; 2021 Jun; 53(6):1623-1631. PubMed ID: 32822095
[TBL] [Abstract][Full Text] [Related]
5. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
[TBL] [Abstract][Full Text] [Related]
6. Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography.
Yin Z; Murphy MC; Li J; Glaser KJ; Mauer AS; Mounajjed T; Therneau TM; Liu H; Malhi H; Manduca A; Ehman RL; Yin M
Eur Radiol; 2019 Nov; 29(11):5823-5831. PubMed ID: 30887196
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric MR Index for the Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease.
Kim JW; Lee YS; Park YS; Kim BH; Lee SY; Yeon JE; Lee CH
Sci Rep; 2020 Feb; 10(1):2671. PubMed ID: 32060386
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).
Han MA; Saouaf R; Ayoub W; Todo T; Mena E; Noureddin M
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):379-390. PubMed ID: 28277807
[TBL] [Abstract][Full Text] [Related]
9. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
[TBL] [Abstract][Full Text] [Related]
10. Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
Ajmera V; Loomba R
Semin Liver Dis; 2018 Feb; 38(1):14-20. PubMed ID: 29471562
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound/Elastography techniques, lipidomic and blood markers compared to Magnetic Resonance Imaging in non-alcoholic fatty liver disease adults.
Cantero I; Elorz M; Abete I; Marin BA; Herrero JI; Monreal JI; Benito A; Quiroga J; Martínez A; Huarte MP; Uriz-Otano JI; Tur JA; Kearney J; Martinez JA; Zulet MA
Int J Med Sci; 2019; 16(1):75-83. PubMed ID: 30662331
[TBL] [Abstract][Full Text] [Related]
12. Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis.
Thavorn K; Coyle D
Ont Health Technol Assess Ser; 2015; 15(19):1-58. PubMed ID: 26664666
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive assessment of non-alcoholic fatty liver disease: ultrasound and transient elastography.
Berzigotti A
Rev Recent Clin Trials; 2014; 9(3):170-7. PubMed ID: 25514917
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of imaging methods for steatohepatitis diagnosis in non-alcoholic fatty liver disease patients: A systematic review.
Besutti G; Valenti L; Ligabue G; Bassi MC; Pattacini P; Guaraldi G; Giorgi Rossi P
Liver Int; 2019 Aug; 39(8):1521-1534. PubMed ID: 30972903
[TBL] [Abstract][Full Text] [Related]
18. Advances in ultrasound elastography for nonalcoholic fatty liver disease.
Yoneda M; Honda Y; Nogami A; Imajo K; Nakajima A
J Med Ultrason (2001); 2020 Oct; 47(4):521-533. PubMed ID: 32748075
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Magnetic Resonance Elastography and Non-Alcoholic Fatty Liver Disease: Time for an Upgrade?
Flores A; Asrani SK
Am J Gastroenterol; 2016 Jul; 111(7):995-6. PubMed ID: 27356823
[TBL] [Abstract][Full Text] [Related]
20. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
Mikolasevic I; Orlic L; Franjic N; Hauser G; Stimac D; Milic S
World J Gastroenterol; 2016 Aug; 22(32):7236-51. PubMed ID: 27621571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
